Skip to content
Screener

Claritev Corporation CTEV Financing Cash Flow

Financing Cash Flow at other companies

Evolent Health, Inc. logo
Evolent Health, Inc.EVH
-$10.99M
UnitedHealth Group logo
UnitedHealth GroupUNH
-$8.62B-8.5%
Conduent Incorporated logo
Conduent IncorporatedCNDT
$30M+400%
Definitive Healthcare Corp. logo
Definitive Healthcare Corp.DH
-$3.02M+87.8%
Corvel logo
CorvelCRVL
-$20.27M-150%
Phreesia logo
PhreesiaPHR
-$26.09M-3,014%

Other financials

Income statement

See full
Revenue$257.5M+6.6%
Gross profit$189.8M+5.0%
Operating income$23.4M+41.2%
Net income-$59.2M+5.5%
EPS (diluted)-$3.49+8.4%

Balance sheet

See full
Cash & equivalents$27.7M-58.9%
Total debt$4.7B+1.0%
Total equity-$294.6M-638%
Total assets$4.8B-6.1%

Cash flow

See full
Operating cash flow$92.7M+51.3%
CapEx$38.1M+54.7%
Free cash flow-$92.5M-34.3%

Valuation

See full
Market cap$555.59M-45.3%
Enterprise value$5.2B-6.7%
P/S0.6×-0.5×

Profitability

See full
Gross margin73%-1.5pp
Operating margin-0.5%-0.3pp
Net margin-28.5%-10.7pp
FCF margin-10.6%

Returns & leverage

See full
Return on equity-198.7%-274pp
Debt / equity310.9×+307×
Current ratio0.0×

Where this comes from

Reported directly by Claritev Corporation in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Claritev Corporation’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001793229-26-000046
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Repayment of 2025 Revolving Credit Facility(40,000)(50,000)
Payment of debt issuance costs(4,267)
Proceeds from issuance of common stock under ESPP464301
Net cash provided by financing activities98,93373,150
Net increase in cash, cash equivalents and restricted cash6,3874,228
Cash, cash equivalents and restricted cash at beginning of period28,34129,672
Cash, cash equivalents and restricted cash at end of period$34,728$33,900
Cash and cash equivalents$21,327$23,129

Item 1. Financial Statements

FAQ

What is Claritev Corporation's financing cash flow?
Claritev Corporation (CTEV) reported financing cash flow of $98.93M in Q1 2026.
How has Claritev Corporation's financing cash flow changed year-over-year?
Claritev Corporation's financing cash flow increased by 35.2% year-over-year, from $73.15M to $98.93M.
What is the long-term trend for Claritev Corporation's financing cash flow?
Over 3 years (2021 to 2024), Claritev Corporation's financing cash flow has grown at a -28.8% compound annual growth rate (CAGR), from -$114.68M to -$41.32M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Claritev Corporation's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude